Do you routinely administer desmopressin to patients with intracerebral hemorrhage who are also on anti-platelet therapy?

I routinely administer desmopressin in patients presenting with ICH if they are on dual antiplatelets but not single antiplatelets. The evidence for this is limited, but it has not revealed any harm.

At our institution, we always administer desmopressin (0.4 micrograms/kg) for patients on anti-platelet therapy with intracranial hemorrhage, regardless of the etiology. There is no high-level data to guide this practice. We performed a retrospective review of patients admitted to the University of ...

We also always administer the higher dose (0.4 mcg/kg) for patients with ICH on antiplatelet agents. This being said, this is institutional practice, and the data is somewhat limited. I think, given it is seen as safe with limited downside, it is commonly used, as opposed to platelet transfusion, fo...